Ann: FORECAST: CVT: Comvita forecast full year earnings to rise more than 35%

  1. lightbulb Created with Sketch. 2
    • Release Date: 23/07/15 14:18
    • Summary: FORECAST: CVT: Comvita forecast full year earnings to rise more than 35%
    • Price Sensitive: No
    • Download Document  4.19KB
    					CVT
    23/07/2015 14:18
    FORECAST
    PRICE SENSITIVE
    REL: 1418 HRS Comvita Limited
    
    FORECAST: CVT: Comvita forecast full year earnings to rise more than 35%
    
    Comvita Chairman Neil Craig announced today at the company's 2015 Annual
    Shareholders Meeting, a revised guidance on future earnings to the end of
    March 2016, signaling an expected increase in net earnings in excess of 35%
    over 2015, and sales in excess of $180 million.
    
    Mr. Craig says today's revised forecast announcement is a strong endorsement
    of the company's growth strategy and high value adding business model, which
    is expected to drive the company towards $400 million in sales by 2020. "The
    current financial year has started well supported by larger than normal raw
    material inventory levels, very strong demand from the market and an active
    process of optimising returns from individual markets and product ranges. We
    believe we will beat the percentage uplift in earnings that we delivered
    during the last fiscal year, and growth in earnings will again outpace growth
    in revenue."  An update to this guidance will be provided at the company's
    six months result announcement in November 2015.
    
    Mr. Craig also advised shareholders that CEO, Brett Hewlett, will step down
    from the helm of the global natural health products company effective 31
    March, 2016.
    
    Hewlett says the timing is right for the transition. "Today, Comvita is a
    world class natural health products company. Our vertically integrated high
    value-add business model is unique within the New Zealand primary industry
    sector. Management and the Board are very satisfied that the objectives that
    we set for the business almost ten years ago around the establishment of the
    business growth model, vertical integration and supply chain development have
    been met. The company is in a strong position with a clear strategy in place
    and a highly competent senior management team that will continue to deliver
    results for shareholders, building on our record 2015 earnings result."
    
    Mr. Craig confirmed Brett's decision has been discussed openly with the Board
    for some time and they have a comprehensive transition plan in place. "Brett
    has built a strong leadership team and has given us plenty of time to plan an
    orderly transition to a new leader. The Board will conduct a process to
    review potential candidates, including internal candidates from the strong
    senior bench of Comvita, and anticipates announcing an appointment before the
    end of 2015."
    
    "We are also pleased to advise that while Brett is exiting the role of CEO,
    he will be invited to join the Board within 12 months of his departure to
    contribute to Comvita's growth journey at the Board level," says Mr. Craig.
    
    # Ends #
    
    For further information:
    Neil Craig, Comvita Chairman, +64 21 731 509
    Brett Hewlett, Comvita CEO, +64 21 740 160
    Julie Chadwick, Comvita Communications Manager, +64 21 510 693
    
    Background information
    About Comvita (www.comvita.com)
    Comvita (NZX:CVT) is a global natural health company committed to the
    development of innovative products, backed by ongoing investment in
    scientific research. We are the world leaders in Manuka (leptospermum) honey
    and fresh-picked Olive Leaf Extract, which are at the core of the Comvita
    product range.
    
    We have approximately 50% of honey supply under direct ownership or control,
    with the balance of supply from long term contractual and partnership
    arrangements. Comvita pioneered the development and use of medical grade
    Manuka honey and was the first to receive FDA approval (2007). We partner
    with US wound care company Derma Sciences, Inc. (NASDAQ:DSCI), the global
    licensee for Medihoney(R) specialist wound care products, which are used in
    hospitals and medical centres around the world. Comvita's freshly picked
    Olive Leaf Extract is grown, harvested, extracted and bottled at the world's
    largest specialised olive leaf grove, with over one million olive trees.
    
    Comvita sells into more than 18 countries through a network of our own
    branded retail locations, online (seven country specific e-commerce websites)
    and third-party outlets. We have over 500 staff located in New Zealand,
    Australia, Hong Kong, Japan, Taiwan, South Korea, the United Kingdom and the
    USA.
    End CA:00267359 For:CVT    Type:FORECAST   Time:2015-07-23 14:18:55
    				
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.